1. BEGIN File 72 to search EMBASE from 1993 to present.

2. EXPAND a term as a word or phrase. Notice the third column, RT, indicates 65 related terms. The Items column shows the number of records that contain the word or phrase.

?b 72

File  72:EMBASE 1993-2008/Oct 08
       (c) 2008 Elsevier B.V.

      Set  Items  Description
      ---  -----  -----------

?e angiogenesis inhibitor

Ref   Items   RT  Index-term
E1        0    1  ANGIOGENESIS INDUCING AGENTS
E2        3    1  ANGIOGENESIS INHIBITION
E3     5964   65 *ANGIOGENESIS INHIBITOR
E4      516       ANGIOGENESIS INHIBITOR --ADVERSE DRUG REACTION
E5     1016       ANGIOGENESIS INHIBITOR --CLINICAL TRIAL --CT
E6       95       ANGIOGENESIS INHIBITOR --DRUG ADMINISTRATION -
E7      331       ANGIOGENESIS INHIBITOR --DRUG ANALYSIS --AN
E8      740       ANGIOGENESIS INHIBITOR --DRUG COMBINATION --CB
E9      398       ANGIOGENESIS INHIBITOR --DRUG COMPARISON --CM
E10     114       ANGIOGENESIS INHIBITOR --DRUG CONCENTRATION --
E11     958       ANGIOGENESIS INHIBITOR --DRUG DEVELOPMENT --DV
E12     505       ANGIOGENESIS INHIBITOR --DRUG DOSE --DO

. . . .

3. Expand E3 to see the related terms in column RT.

The first 50 related terms appear. The letters in the third column, Type, identifies synonyms, broader and narrower terms. The narrower terms appear to be drug names, laboratory codes and chemical names (not shown here). You can select appropriate R number terms or just browse the list.

When you PAGE down (P) the R reference numbers start over as R1, so it is important to SELECT the R numbers you want before entering P (not shown here).

4. Use Dialog’s EXPLODE command by appending an exclamation point (!) to the end of the phrase. This automatically SELECTS the main term and all of its narrower (N) terms, including the ones that fell after R50.

Use database LIMIT features by restricting results to major focus about human subjects in English.

?e e3

Ref   Items Type  RT  Index-term
R1     5964       65 *ANGIOGENESIS INHIBITOR
R2        0   S    1  ANGIOGENESIS INHIBITORS
R3        0   S    1  ANTIANGIOGENIC AGENT
R4        0   S    1  ANTIANGIOGENIC DRUG
R5        0   S    1  NEOVASCULARIZATION INHIBITOR
R6        0   S    1  TUMOR VASCULARIZATION INHIBITOR
R7        0   S    1  VASCULARIZATION INHIBITOR
R8    76371   B 1450  ANTINEOPLASTIC AGENT
R9     3558   B 1381  CARDIOVASCULAR AGENT
R10     339   N   11  AE 941
R11     186   N    9  ANECORTAVE
R12      42   N    2  ANGIOSTATIC PROTEIN
R13    1361   N    4  ANGIOSTATIN
R14     131   N    2  ANGIOZYME
. . . .
R44    2101   N   13  SORAFENIB
R45     305   N    6  SQUALAMINE
R46    1915   N   21  SUNITINIB
R47     378   N   12  TANOMASTAT
R48    1413   N    6  THROMBOSPONDIN 1
R49     241   N    6  THROMBOSPONDIN 2
R50     111   N    6  TUMSTATIN 

Enter P or PAGE for more

?s angiogenesis inhibitor!/maj,human,eng
      S1    4851  ANGIOGENESIS INHIBITOR!/MAJ,HUMAN,ENG

5. EXPAND the next concept. There is one related term, but there are no records that contain this phrase. Notice the dearth of items for the terms below.

?e ovarian cancer

Ref   Items   RT  Index-term
E1        2       OVARIAN BORDERLINE TUMOR
E2        1       OVARIAN BURKITT LYMPHOMA
E3        0    1 *OVARIAN CANCER
E4        1       OVARIAN CANCER ANTIGEN
E5        1       OVARIAN CANCER ANTIGEN (CA 125) MAGIA
E6        1       OVARIAN CANCER ANTIGEN (CA 125) MAGIA L
E7       10       OVARIAN CANCER G PROTEIN COUPLED RECEPTOR 1
E8        1       OVARIAN CANCER IMMUNOREACTIVE ANTIGEN DOMAIN C

. . . .

6. EXPAND the appropriate E reference number. The letter U under the Type column means USE this term. Look at the number of records now with the EMTREE preferred term.

A trick to use in EMTREE, once you know how it works, is to bypass the first EXPAND. Enter EXPAND (<term>) enclosed in parentheses. For example, EXPAND (OVARIAN CANCER). If it is an EMTREE term or has related terms, it will take you right to the EMTREE screen.

7. Use EXPLODE by SELECTing the preferred term and appending an exclamation point to the end of the term or phrase. If the term does not have narrower terms, Dialog will SELECT the phrase and provide a message that there are no narrower terms.

?e e3

Ref   Items Type  RT  Index-term

R1        0        1 *OVARIAN CANCER
R2    19489   U   12  OVARY CANCER

Enter P or PAGE for more

?select ovary cancer!/maj,human,eng
      S3   15420 OVARY CANCER!/maj,human,eng

8. Combine Sets 1 and 2 (S1, S2) so that each record will contain both concepts limited to major focus, human subjects and English language.

9. Use database LIMITS to restrict retrieval to a range of publication years. The colon acts as OR.

?s s1 and s2
            5068  S1
           15668  S2
      S3      69  S1 AND S2

?s s3/2007:2008
              69  S3
          995036  PY=2007 : PY=2008
      S4      23  S3/2007:2008

10. TYPE records in Format 8 to browse titles, indexing and publication years.

Some records index manufacturers and brand names.

To select the appropriate record number, look at the range of records in the TYPE command (e.g., 4/8/2).

Note: Some portions of the records have been omitted from the display.

?t s4/8/1-2

4/8/1
DIALOG(R)File 72: EMBASE
(c) 2008 Elsevier B.V. All rights reserved.

0082506813     EMBASE No: 2008349512
  Antiangiogenic therapy and ovarian cancer

 Publication Date: February 1, 2008
Brand Name/Manufacturer: abt 627; ae 941; avastin/Genentech/United States; azd 2171; bay 43 9006; cytoxan; doxil; erbitux; evizon/Genaera; genexol; gw 786034; neovastat; nexavar; osi 774; ptk 787; pxd 101/CuraGen; recentin; su 11248; sutent; tarceva; xinlay; zk 222584
Manufacturer name: CuraGen; Genaera; Genentech/United States
Drug Descriptors:
* angiogenesis inhibitor--adverse drug reaction--ae; *angiogenesis inhibitor --drug therapy--dt; *angiogenesis inhibitor--pharmacoeconomics--pe; * angiogenesis inhibitor--pharmacology--pd
. . . .

4/8/2
DIALOG(R)File 72: EMBASE
(c) 2008 Elsevier B.V. All rights reserved.

0082504852     EMBASE No: 2008309848
  Posterior reversible encephalopathy syndrome during sunitinib therapy

 Publication Date: June 1, 2008
Brand Name/Manufacturer: sutent/Pfizer/United States
Manufacturer name: Pfizer/United States
Drug Descriptors:
* sunitinib--adverse drug reaction--ae; *sunitinib--drug therapy--dt
clonazepam; fosphenytoin sodium; gadolinium
Medical Descriptors:
* kidney carcinoma--drug therapy--dt; *ovary metastasis--drug therapy--dt abdominal pain--side effect--si; adult; antiangiogenic therapy; article; . . . .

11. TYPE Set 4 (S4), Record 2 in Format 9 to display the complete record.

EMBASE provides the author’s contact information.

EMBASE also provides a Digital Object Identifier, which connects you to the journal publisher’s website where you may purchase the fulltext or obtain it if you have an electronic journal subscription.

Note: Part of this record is omitted from the display.

?t s4/9/2

4/9/2
DIALOG(R)File 72: EMBASE
(c) 2008 Elsevier B.V. All rights reserved.

0082504852     EMBASE No: 2008309848
  Posterior reversible encephalopathy syndrome during sunitinib therapy

  Cumurciuc R.; Martinez-Almoyna L.; Henry C.; Husson H.; de Broucker T. Service de neurologie, hopital Delafontaine, 2, rue du Dr-Delafontaine, 93200 Saint-Denis, France
 Author email: thomas.debroucker@ch-stdenis.fr
 Corresp. Author/Affil: de Broucker T.: Service de neurologie, hopital Delafontaine, 2, rue du Dr-Delafontaine, 93200 Saint-Denis, France
 Corresp. Author Email: thomas.debroucker@ch-stdenis.fr

  Revue Neurologique ( Rev. Neurol. ) ( France )   June 1, 2008 , 164/6-7 (605-607)
  CODEN: RENEA   ISSN: 0035-3787
 Publisher Item Identifier: S0035378708002932
Item Identifier (DOI): 10.1016/j.neurol.2008.03.007
  Document Type: Journal ; Article  Record Type: Abstract
  Language: English   Summary language: English; French
 Number of References: 11

  A case of posterior reversible encephalopathy syndrome (PRES) occurring in a women treated by sunitinib for an ovarian metastatis of a renal cell carcinoma is described. This is the third case described in the literature. The three cases are very similar except for the delay to onset of the PRES (one week to five months). Both antiangiogenic and prohypertensive effects of sunitinib are probably involved in the pathophysiology of PRES. Physicians should be aware of this potentially life-threatening side-effect of sunitinib easily controlled by withdrawing sunitinib and symptomatic treatment. (c) 2008 Elsevier Masson SAS. All rights reserved.
. . . .